SCHEMBL3666735

SCHEMBL3666735

CCOc1cc(Nc2nc(N[C@@H](CO)c3ccc(F)cn3)ccc2[N+](=O)[O-])n[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 9/20 0.49
KCNH2 Q12809 2/20 0.43
JAK3 P52333 6/20 0.40
JAK2 O60674 6/20 0.40
BRD4 O60885 2/20 0.37
AURKA O14965 3/20 0.37
GRK6 P43250 3/20 0.37
IGF1R P08069 2/20 0.37
GRK4 P32298 1/20 0.37
GRK5 P34947 1/20 0.37
GRK1 Q15835 1/20 0.37
GRK7 Q8WTQ7 1/20 0.37
CDK2 P24941 2/20 0.36
MUSK O15146 1/20 0.36
LCK P06239 1/20 0.36
RET P07949 1/20 0.36
FGFR3 P22607 1/20 0.36
CCNE1 P24864 1/20 0.36
FLT3 P36888 1/20 0.36
PTK2B Q14289 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3766933 0.91 NTRK1 (0.50) NTRK1KCNH2JAK3JAK2BRD4
SCHEMBL3012333 0.88 NTRK1 (0.43) NTRK1KCNH2JAK3JAK2AURKA
SCHEMBL3024160 0.81 NTRK1 (0.42) NTRK1KCNH2JAK3JAK2AURKA
SCHEMBL3008289 0.79 NTRK1 (0.44) NTRK1KCNH2JAK3JAK2AURKA
SCHEMBL2572976 0.79 NTRK1 (0.56) NTRK1KCNH2BRD4GRK6CDK2
SCHEMBL2572982 0.79 NTRK1 (0.56) NTRK1KCNH2BRD4GRK6CDK2
SCHEMBL3018456 0.76 JAK3 (0.54) NTRK1JAK3JAK2AURKACDK2
SCHEMBL4697204 0.76 NTRK1 (0.58) NTRK1JAK3JAK2BRD4AURKA
SCHEMBL4697209 0.76 NTRK1 (0.58) NTRK1JAK3JAK2BRD4AURKA
SCHEMBL3663952 0.75 FGFR4 (0.46) NTRK1BRD4AURKAIGF1RFGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150011545-A1 Chemical Compounds - 759 ASTRAZENECA AB (SE) 2015-01-08 US disclosed
US-20140155394-A1 Chemical Compounds - 759 ASTRAZENECA AB (SE) 2014-06-05 US disclosed
US-8486966-B2 9-(pyrazol-3-yl)-9H-purine-2-amine and 3-(pyrazol-3-yl) -3H-imidazo[4,5-B] pyridin-5-amine derivatives and their use for the treatment of cancer ASTRAZENECA AB (SE) 2013-07-16 US disclosed
US-20100324040-A1 9-(PYRAZOL-3-YL)-9H-PURINE-2-AMINE AND 3-(PYRAZOL-3-YL) -3H-IMIDAZO[4,5-B] PYRIDIN-5- AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER ASTRAZENECA AB 2010-12-23 US disclosed
EP-2152705-A1 9- (PYRAZOL- 3 -YL) - 9H- PURINE-2 -AMINE AND 3- (PYRAZ0L-3-YL) -3H-IMIDAZ0 [4, 5-B]PYRIDIN-5-AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER AstraZeneca AB (SE) 2010-02-17 EP disclosed
WO-2008135785-A1 9- (PYRAZOL- 3 -YL) - 9H- PURINE-2 -AMINE AND 3- (PYRAZ0L-3-YL) -3H-IMIDAZ0 [4, 5-B] PYRIDIN-5-AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150011545-A1 Chemical Compounds - 759 MCL1, BCL9, BCL9L NTRK1 4667/4885KCNH2 3216/4885JAK3 363/4885
US-20140155394-A1 Chemical Compounds - 759 MCL1, BCL9, BCL9L NTRK1 4667/4885KCNH2 3216/4885JAK3 363/4885
US-20100324040-A1 9-(PYRAZOL-3-YL)-9H-PURINE-2-AMINE AND 3-(PYRAZOL-3-YL) -3H-IMIDAZO[4,5-B] PYRIDIN-5- AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER THPO, MPL, MCL1 NTRK1 4038/4885KCNH2 1842/4885JAK3 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.